VASH1 Antibody

1. Low VASH1 expression is associated with angiogenesis and tumor growth in renal cell carcinoma. PMID: 28656230
2. VASH1 is a prognostic marker in ovarian carcinoma. PMID: 29057763
3. VASH1 and VASH2 but not SVBP alone, increased detyrosination of -tubulin, and purified vasohibins removed the C-terminal tyrosine of -tubulin. PMID: 29146869
4. High serum prolactin and vasoinhibin levels predict and may impact retinopathy of prematurity progression PMID: 27842054
5. Studied angiogenic activity of vasohibin-1 (VASH1), by analyzing levels of VASH1 in both RCC tissue and non-neoplastic kidney tissue. Found elevated VASH1 density, but not microvascular density, was a significant and independent predictor of overall survival in RCC. PMID: 28287633
6. identified a novel UPS regulatory system in which essential domain architecture (VASH-PS) of VASHs, comprising regions VASH191-180 and VASH280-169 , regulate the cytosolic punctate structure formation in the absence of SVBP. PMID: 27879017
7. replicative senescence, the downregulation of VASH1 expression in endothelial cells was caused, at least in part, by the alteration of microRNA expression. PMID: 27325558
8. VASH1 expression is associated with tumour progression and may be useful as a prognostic marker of head and neck squamous cell carcinoma PMID: 28314285
9. VASH1 expression inhibited tumor vascularization and growth, not only in high VEGF-producing cells, but also in high PDGF-producing cells, reduced their peritoneal dissemination and ascites, and prolonged the survival time of the host PMID: 26893100
10. in this study, the length of tube forming structures of endothelial cells in vitro showed that Vasohibin-1 expression in gastric cancer cells significantly decreased the ability of vessel formation of endothelium cells. PMID: 26666821
11. These results indicate that cancer cells proteolytically inactivate VASH1 protein secreted by ECs in the tumour microenvironment PMID: 27169581
12. Our present findings on VASH1A and VASH1B should provide an innovative approach that would improve the efficacy of antiangiogenic cancer therapy by balancing vascular normalization and pruning. PMID: 27080222
13. VASH1 exerts an antitumor effect on ovarian cancer by inhibiting angiogenesis in the tumor environment PMID: 26460696
14. VASH1 expression levels in atheroma reflects both enhanced neovascularization and the inflammatory burden PMID: 25843115
15. Knockdown of VASH1 in cancer cells promoted cell growth, adhesion and migration in vitro, and enhanced tumorigenesis and metastasis in vivo. PMID: 25797264
16. VASH1 and VASH2 showed distinctive localization and opposing function on the fetoplacental vascularization. PMID: 25184477
17. These results suggest that the renal levels of VASH-1 may be affected by local inflammation, crescentic lesions and VEGFR-2. PMID: 25145408
18. High VASH1 expression is associated with non-small cell lung cancer. PMID: 24748406
19. Overexpression of VASH1 in CRC cells increased malignant potential and promoted metastasis. PMID: 25275025
20. We found that vasohibin-1 and VEGF are up-regulated, in mesentery and liver, in cirrhotic and precirrhotic portal hypertensive rats and cirrhosis patients. PMID: 24390792
21. High Vasohibin-1 expression is associated with colorectal cancer. PMID: 24366689
22. Vasohibin 1/CD34 could identify the proliferative vessels and could be a useful biomarker for predicting the clinical outcome of hepatocellular carcinoma patients. PMID: 24444468
23. Data show expression of TGF-beta1, TGF-beta2, BMP-4, and BMP-7 was increased in tumor-associated macrophages (TAMs) cocultured with pancreatic cancer cells, and vasohibin-1, VEGF-A, and vVEGF-C expression in pancreatic cancer cells was upregulated by TAMs. PMID: 23651239
24. Vasohibin-1 is a new predictor of disease-free survival in operated patients with renal cell carcinoma. PMID: 23543668
25. Vasohibin-1 and VEGF-A are the most important factors influencing the dismal prognosis based on the modulation of angiogenesis in hepatocellular carcinoma (HCC). PMID: 22101788
26. vasohibin-1 and vasohibin-2 mRNA are expressed in gastric cancer cells and in tumor-associated macrophages (TAMs), and their expressions are altered by hypoxia. PMID: 22438034
27. VASH1 density represents a clinically relevant predictor of patient prognosis and can be a new biomarker that would provide additional prognostic information in prostate cancer. PMID: 23591203
28. we postulate that VASH1 would potentially be a biomarker and a candidate for molecular targeted therapy for patients with renal cell carcinoma PMID: 22865127
29. novel candidate master regulator of endothelial cell apoptosis PMID: 23324451
30. VASH1 is a critical factor that improves the stress tolerance of ECs via the induction of SOD2 and SIRT1 PMID: 23056314
31. Data suggest that VASH1 is expressed in vascular endothelium to terminate angiogenesis; VASH2 appears to be expressed in other cells (primarily mononuclear leukocytes) to promote angiogenesis. [REVIEW] PMID: 23100270
32. Results suggest that Vasohibin-1 (VASH1)density could become a new biomarker and provide additional prognostic information in patients with upper urinary tract urothelial carcinomas (UTUC). PMID: 22675166
33. Transgene expression of VASH1 in the recipient lung significantly attenuated luminal obliteration of the tracheal allograft and significantly reduced aberrant angiogenesis. PMID: 22564651
34. Data suggest that vasohibin inhibits cell proliferation of umbilical vein endothelial cells through degradation of HIF-1alpha via proline hydroxylase during oxidative stress. Vasohibin may be a negative feedback regulator of angiogenesis. PMID: 22569265
35. Reduced vasohibin and VEGF expression may be responsible, at least in part, for the impaired vascular development which occurs during pre-eclampsia. PMID: 21302448
36. SVBP(CCDC23)acts as a secretory chaperone for VASH1. PMID: 20736312
37. vasohibin1 is the first known intrinsic factor having broad-spectrum antilymphangiogenic activity PMID: 20133819
38. This review focuses on negative regulators of angiogenesis delta-like 4 and vasohibin 1 produced by endothelial cells. PMID: 20167561
39. These results suggest that vasohibin-1 is expressed in RA synovial tissue and might be regulated by inflammatory cytokines. PMID: 20035291
40. Results suggest that KIAA1036, or vasohibin, is an endothelium-derived negative feedback regulator of angiogenesis [vasohibin] PMID: 15467828
41. Recombinant amino-terminal truncated forms of vasohibin retain inhibitory activity of angiogenesis in mouse corneal assay and show strong affinity to heparin. PMID: 16488400
42. vasohibin has an activity to prevent neointimal formation by inhibiting adventitial angiogenesis PMID: 16707096
43. expression of vasohibin in the stromal endothelial cells in human carcinomas. PMID: 18325046
44. vasohibin-1 is associated with neovascularization and may especially play important roles in the regulation of intratumoral angiogenesis in human breast cancer. PMID: 19037993
45. Hypoxia induces VEGF, which induces the production of vasohibin-1 in endothelial cells and inhibits angiogenesis as a negative feedback regulator. PMID: 19057892
46. These results suggest a role for VASH1 in negative feedback regulation of haematopoietic progenitors proliferation during recovery following bone marrow ablation. PMID: 19179360
47. These results suggest that endogenous vasohibin-1 is involved in tumor angiogenesis and exogenous vasohibin-1 blocks sprouting angiogenesis by tumors, matures the remaining vessels, and enhances the antitumor effect of conventional chemotherapy PMID: 19498005
48. Streptozotocin- induced type 1 diabetic mice received intravenous injections of adenoviral vectors encoding VASH-1, which suppressed diabetic retinopathy. PMID: 19587360
49. Overexpression of human VASH1 inhibited angiogenic sprouting and supports vascular maturation processes in vivo. PMID: 19682397

显示更多

收起更多

HGNC: 19964

OMIM: 609011

KEGG: hsa:22846

STRING: 9606.ENSP00000167106

UniGene: Hs.525479